| Literature DB >> 33268937 |
Venkatesh Sudharsan Vaithiyam1, Neha Rastogi2, Piyush Ranjan1, Niranjan Mahishi2, Arti Kapil3, Sada Nand Dwivedi4, Manish Soneja1, Naveet Wig1, Ashutosh Biswas1.
Abstract
Background The global burden of infections due to multidrug-resistant organism (MDRO) has a significant impact on patients' morbidity and mortality along with increased healthcare expenditure. Aim This article estimates the prevalence of MDRO and the spectrum of clinical infectious syndromes caused by these organisms in medical wards of a tertiary care hospital in India. Design and Methods A cross-sectional observational study was performed among patients admitted in medicine wards diagnosed with the various infectious syndromes and one or more clinically significant positive culture at a tertiary care hospital in North India over a period of 18 months. Results Out of 323 clinically significant microbiological culture isolates from 229 patients included in the study, 86 (27%) isolates showed multidrug resistance (MDR) pattern, 197 (61%) isolates showed possible extremely drug-resistance pattern, and only 40 (12%) isolates showed nonmultidrug-resistance pattern of antibiogram. Conclusion The prevalence of MRDOs is high in clinically significant culture isolates from medicine wards in India. This emphasizes the importance of appropriate antibiotic usage and implementation of antibiotic stewardship programs in this part of the world. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.).Entities:
Keywords: antimicrobial resistance, antibiogram; drug-resistant infections
Year: 2020 PMID: 33268937 PMCID: PMC7684999 DOI: 10.1055/s-0040-1721161
Source DB: PubMed Journal: J Lab Physicians ISSN: 0974-2727
Distribution of pathogens in different spectrum of infections ( n = 323)
| Sr. no. | Infection | Isolates | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| Others | Total (%) | ||
| Abbreviations: BSI, blood stream infections; CAP, community-acquired pneumonia; CA-UTI, catheter-associated urinary tract infection; CLABSI, central line-associated blood stream infection; HAP, hospital-acquired pneumonia; PBSI, primary blood stream infection; RTI, respiratory tract infections; S-BSI, secondary blood stream infection; SSTI, skin and soft tissue infection; UTI, urinary tract infection; S-UTI, symptomatic urinary tract infection; VAP, ventilator-associated pneumonia. | |||||||||
| A | 1. RTI | 68 | 36 | 15 | 13 | 0 | 1 | 6 | 139(43) |
| 1.1 CAP | 0 | 3 | 0 | 1 | 0 | 0 | 0 | 4(1.2) | |
| 1.2 HAP | 12 | 6 | 6 | 7 | 0 | 0 | 1 | 32(9.9) | |
| 1.3 VAP | 56 | 26 | 7 | 3 | 0 | 0 | 3 | 95(29.4) | |
| 1.4 Pleural effusion | 0 | 1 | 2 | 2 | 0 | 1 | 2 | 8 (2.47) | |
| B | 2. UTI | 1 | 19 | 0 | 43 | 0 | 8 | 7 | 78(24.1) |
| 2.1 S-UTI | 0 | 5 | 0 | 25 | 0 | 1 | 0 | 31(9.5) | |
| 2.2 CA-UTI | 1 | 14 | 0 | 20 | 0 | 7 | 5 | 47 (14.5) | |
| C. | 3. BSI | 17 | 22 | 1 | 13 | 2 | 6 | 12 | 73(22.6) |
| 3.1 P-BSI | 5 | 8 | 0 | 10 | 0 | 5 | 2 | 30 (9.28) | |
| 3.2 S-BSI | 11 | 4 | 1 | 1 | 2 | 0 | 10 | 29 (8.97) | |
| 3.3 CLABSI | 1 | 10 | 0 | 2 | 0 | 1 | 0 | 14 (4.33) | |
| D. | 4. SSTI | 5 | 3 | 5 | 2 | 5 | 0 | 1 | 20 (6.19) |
| E. | 5. Sterile site infection | 1 | 3 | 1 | 3 | 0 | 0 | 0 | 8(2.4) |
| 5.1 Meningitis | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 4 (1.2) | |
| 5.2 Cholangitis | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 (0.3) | |
| 5.3 Ascites | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 3 (0.9) | |
| Total | 92 | 86 | 22 | 75 | 7 | 15 | 16 | 323 | |
Drug resistance patterns among various culture isolates
| Bacteria | Nonmultidrug resistant | Multidrug resistant | Possible extensive drug resistant | Total |
|
|---|---|---|---|---|---|
|
Note:
| |||||
|
| 1 (1) | 9 (10) | 82 (89) | 92 | < 0.0001 |
|
| 5 (6) | 11 (13) | 70 (81) | 86 | <0.0001 |
|
| 6 (27) | 2 (9) | 14 (64) | 22 | 0.032 |
|
| 12 (16) | 42 (56) | 21 (28) | 75 | < 0.0001 |
|
| 0 | 10(66.67) | 5(33.33) | 15 | < 0.003 |
|
| 1 | 0 | 1 | 2 | – |
|
| 3 (30) | 7 (70) | 0 | 10 | 0.001 |
| Others | |||||
|
| 9 (90) | 1 (10) | 0 | 10 | < 0.001 |
|
| 2 | 1 | 1 | 4 | 0.016 |
|
| 1 | 1 | 1 | 3 | 0.295 |
|
| 0 | 1 | 0 | 1 | – |
|
| 0 | 1 | 2 | 3 | 0.630 |
| Total | 40 (12) | 86 (27%) | 197(61%) | 323 | |
Distribution of drug resistance in different spectrum of infection
| Sr. no. | Clinical condition | Number (%) of clinically significant culture isolates | ||||
|---|---|---|---|---|---|---|
| NMDR | MDR | P-XDR | Total | |||
| Abbreviations: CAP, community-acquired pneumonia; CA-UTI, catheter-associated urinary tract infection; CLABSI, central line-associated blood stream infection; HAP, hospital-acquired pneumonia; MDR, multidrug resistant; NMDR,nonmultidrug resistant; P-XDR, possible extensive drug resistant; PBSI, primary blood stream infection; S-BSI, secondary blood stream infection; S-UTI, symptomatic urinary tract infection; SSTI, skin and soft tissue infection; VAP, Ventilator associated pneumonia. | ||||||
| A. | 1. Respiratory tract infection | 12 | 17 | 110 | 139 (43%) |
|
| 1.1 CAP | 3 | 1 | 0 | 4 | – | |
| 1.2 HAP | 5 | 3 | 24 | 32 | ||
| 1.3 VAP | 0 | 13 | 82 | 95 | ||
| 1.4 Pleural fluid | 4 | 0 | 4 | 8 | ||
| B. | 2. Urinary tract infection | 11 | 41 | 30 | 82 (25%) |
|
| 2.1 S-UTI | 8 | 20 | 7 | 35 | – | |
| 2.2 CA-UTI | 3 | 21 | 23 | 47 | ||
| C. | 3. Blood stream infection | 2 | 29 | 42 | 73(22.6%) |
|
| 3.1 P-BSI | 2 | 13 | 15 | 30 | – | |
| 3.2 S-BSI | 0 | 13 | 16 | 29 | ||
| 3.3 CLABSI | 0 | 3 | 11 | 14 | ||
| D. | 4. Others | 5 | 9 | 15 | 29 (8%) |
|
| 4.1 SSTI | 5 | 6 | 10 | 21 | – | |
| 4.2 Meningitis | 0 | 1 | 3 | 4 | ||
| 4.3 Cholangitis | 0 | 1 | 0 | 1 | ||
| 4.4 Peritonitis | 0 | 1 | 2 | 3 | ||
Antimicrobial resistance patterns of commonly observed Gram-negative isolates (%)
| Sr.no. | Pathogen | Ciplo | Ami | Netli | Cefo | Ceftaz | Cef-Sul | Imi | Mero | Amoxcalv | Piptaz | Colistin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbreviations: Ami, amikacin; Amoxcalv, amoxicillin clavulanic acid; Cefo, cefotaxime; Cef-Sul, cefoperazone/sulbactam; Cefta, ceftazidime; Ciplo, ciprofloxacin; Imi, imipenem; Mero, meropenem; Netli, Netlimicin; NT, not tested; Piptaz, piperacillin/tazobactam. | ||||||||||||
| 1 |
| 98.9 | 98.9 | 89.4 | 100 | 100 | 34.7 | 90.1 | 77.17 | 100 | 98.8 | 0 |
| 2 |
| 96.5 | 84.8 | 83 | 97.6 | 96.4 | 72.9 | 43 | 83.7 | 100 | 85.71 | 0 |
| 3 |
| 93.6 | 40.5 | 36 | 90.14 | 88 | 39.43 | 24.32 | 80.5 | 90.62 | 86.48 | 0 |
| 4 |
| 66.6 | 68.2 | 69.2 | 85.71 | 77.27 | 63.63 | 50 | 63.63 | NT | 63.63 | 0 |
| 5 |
| 60 | NT | NT | 10 | 0 | NT | NT | NT | NT | NT | NT |
Antimicrobial resistance patterns of commonly observed Gram-positive isolates (%)
| Sr. no. | Pathogen | Peni | Amocalv | Ciplox | Eryth | Genta | Ami | Line | Teico | Van | Tetra | Co-Tri |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbreviations: Ami, amikacin; Amocalv, amoxicillin clavulanic acid; Ciplox, ciprofloxacin; Co-Tri,co-trimoxazole; Eryth, erythromycin; Genta, gentamicin; Line, linezolid; NT, not tested; Peni, penicillin; Teico, teicoplanin; Tetra, tetracycline; Van, vancomycin. | ||||||||||||
| 1. |
| 76.9 | NT | 100 | 100 | 100 | NT | 6.67 | 33.3 | 34.1 | 33.3 | 0 |
| 2. |
| 77.7 | 66.67 | 70 | 66.67 | 50 | 22.2 | 0 | 0 | 0 | NT | 60 |
Antibiotic resistance patterns of common Gram-negative isolates among various spectrums of infections (%)
| Sr. no. | Infection | Ciplo | Ami | Netli | Cefo | Ceftaz | Cef-Sul | Imi | Mero | Amoxclav | Piptaz | Colistin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbreviations: Ami, amikacin; Amoxcalv, amoxicillin clavulanic acid; CAP, community-acquired pneumonia; CA-UTI, catheter-associated urinary tract infection; CLABSI, central line-associated blood stream infection; Cefo, cefotaxime; Cef-Sul, cefoperazone/sulbactam; Ceftaz- ceftazidime; Ciplo, ciprofloxacin; HAP, hospital-acquired pneumonia; Imi, imipenem; Mero, meropenem; Netli, Netlimicin; NT, not tested; P-BSI, primary blood stream infection; Piptaz, piperacillin/tazobactam; S-BSI, secondary blood stream infection; S-UTI, symptomatic urinary tract infection; VAP, ventilator-associated pneumonia. | ||||||||||||
| 1. | CAP | 75 | 25 | 25 | 100 | 50 | 0 | 0 | 25 | NT | 0 | NT |
| 2. | HAP | 87 | 81 | 62 | 100 | 93.75 | 40 | 69 | 81 | 100 | 78 | 0 |
| 3. | VAP | 98 | 96 | 92 | 100 | 98 | 49 | 70.5 | 78 | 89 | 96 | 0 |
| 4. | S-UTI | 89.2 | 23.3 | 31 | 85.2 | 86.6 | 27.5 | 20.6 | 68.6 | 82.3 | 58.6 | NT |
| 5. | CA-UTI | 97.7 | 62.6 | 62.8 | 94.4 | 91.8 | 59.4 | 16.2 | 86.4 | 100 | 86.4 | 0 |
| 6. | P-BSI | 96 | 73 | 60 | 100 | 100 | 67 | 50 | 86 | 100 | 87 | 0 |
| 7. | S-BSI | 85 | 100 | 67 | 67 | 90 | 59 | 88 | 882.3 | 100 | 94 | 0 |
| 8. | CLABSI | 100 | 91 | 100 | 100 | 100 | 92 | 58 | 100 | 100 | 92 | 0 |